Table 1.
Clinical histories of glioma patients
| Case ID | GBM-1 | AA-1 | AO-1 |
| Gender | M | F | M |
| Age at the time of Dx | 55 | 51 | 58 |
| KPS at the time of Dx | 70% | 80% | 60% |
| Symptoms | Aphasia | Seizure | Hemi-paresis, seizure |
| Histology | GBM | AA | AO |
| Time from Dx to PBMC sampling | 24 mos | 153 mos | 82 mos |
| Tumor location | Lt. hemisphere | Lt. temporal lobe | Lt. frontal lobe |
| Treatment | Bx | Bx | Bx, cystic aspiration |
| FEBRT | FEBRT | FEBRT | |
| TMZ/CPT-11 (7 cycles) | BCNU/CDDP/VP-16 (4 cycles) | PCV (3 cycles), TMZ | |
| Time to progression from the Dx | 3 mos | No progression for 153 mos | 12 mos |
| Current status of tumor | Progressive disease | No Gd-enhancing lesion | Progressive disease |
M; male, F; female, GBM; glioblastoma, AO; anaplastic oligoastrocytoma, mos; months, Bx; biopsy, Dx; diagnosis, KPS; Karnofsky performance status, FEBRT; fractionated external beam radiation therapy, Gd; Gadolinium, TMZ; temozolomide, PCV; procarbazine, lomustine and vincristine, CPT-11; irinotecan, BCNU; bischloroethylnitrosourea, CDDP; cisplatin, VP-16; etoposide.